Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | CRHBP | P24387 | 1/20 | 0.51 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 7/20 | 0.45 |
| ▸ | BCHE | P06276 | 6/20 | 0.45 |
| ▸ | TAS2R14 | Q9NYV8 | 2/20 | 0.44 |
| ▸ | SLC1A5 | Q15758 | 1/20 | 0.44 |
| ▸ | TSPO | P30536 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5391303 | 0.85 | BCHE (0.45) | ALDH1A1HTTL3MBTL1ACHEBCHE | |
| SCHEMBL3382241 | 0.81 | SMN1; SMN2 (0.49) | MEN1KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL5403330 | 0.79 | MEN1 (0.53) | MEN1KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL8933614 | 0.75 | MEN1 (0.51) | MEN1KMT2ACRHBPCRHR2ALDH1A1 | |
| SCHEMBL6270222 | 0.74 | MEN1 (0.44) | MEN1KMT2ACRHBPCRHR2L3MBTL1 | |
| SCHEMBL15118580 | 0.72 | MEN1 (0.61) | MEN1KMT2ACRHBPCRHR2ALDH1A1 | |
| Bicarbonate SCHEMBL27683066 | 0.71 | MTNR1A (0.54) | MEN1KMT2AALDH1A1HTTL3MBTL1 | |
| SCHEMBL21306338 | 0.71 | MEN1 (0.56) | MEN1KMT2ACRHBPCRHR2ALDH1A1 | |
| SCHEMBL1845830 | 0.71 | MEN1 (0.52) | MEN1KMT2ACRHBPCRHR2ALDH1A1 | |
| SCHEMBL9781306 | 0.70 | MEN1 (0.52) | MEN1KMT2ACRHBPCRHR2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7727997-B2 | N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives | ELAN PHARMACEUTICALS, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| US-20070213316-A1 | Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease | ELAN PHARMACEUTICALS, INC. | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213316-A1 | Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease | BACE1, BACE2, APP | MEN1 2356/4885KMT2A 4650/4885CRHBP 2384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.